BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 30, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Moderna COVID-19 vaccine

Unanimous booster vote more a desire to avoid confusion

Oct. 14, 2021
By Mari Serebrov
Given the FDA’s Vaccines and Related Biological Products Advisory Committee’s unanimous vote last month to recommend use of a booster dose of the Pfizer Inc.-Biontech SE COVID-19 vaccine in certain high-risk groups, it came as no surprise when the committee again voted unanimously Oct. 14 for a mirror use of Moderna Inc.’s proposed booster.
Read More

Regulatory actions for Oct. 14, 2021

Oct. 14, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adocia, Algernon, Asieris, Beigene, Blade, Cantargia, Eli Lilly, Homology, Kadimastem, Lundbeck, Merck, Otsuka, Pharmather, Regeneron, Revance, Roche, Sanofi, Sorrento, Viridian.
Read More

Other news to note for Oct. 14, 2021

Oct. 14, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aluda, Ardelyx, Augmenta, Aurigene, Biolinerx, Biomx, BMS, Eli Lilly, Emerald, Eqrx, Evotec, Exelixis, Graphite, Hemogenyx, HNF, Lixte, Maruho, NLS, Omega, Pasithea, Rarebase, Regulus, Skye, Stanford, Storm, Synlogic, Teva, Turning Point.
Read More

In the clinic for Oct. 14, 2021

Oct. 14, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 60 Degrees, Alimera, Anavex, Apnimed, Atara, Biogen, BMS, Brainstorm, Crispr, EMD, Eyepoint, Faraday, First Wave, Genentech, Horizon, I-Mab, Immune-Onc, Immunitybio, Neoimmunetech, Neurobo, Oncolytics, Oryzon, Outlook, Resverlogix, Rhizen, Sanofi, Smart Immune, TC, Tizona, Ultimovacs, Union, VBI, Veru, Vistagen.
Read More
Syringe with Johnson & Johnson logo

FDA briefing docs build stronger case for 2nd J&J vaccine dose

Oct. 13, 2021
By Mari Serebrov
Should Johnson & Johnson’s (J&J) COVID-19 vaccine be a two-dose series? While not directly asked, that question almost lurks between the lines of the FDA’s briefing document for the Oct. 15 meeting of its Vaccines and Related Biological Products Advisory Committee. The document referred to J&J’s proposed second dose as a “booster,” but the FDA isn’t asking the committee the questions it posed for the Moderna Inc. and Pfizer Inc.-Biontech SE boosters. Instead, it is inviting VRBPAC to advise on whether the second J&J dose should be administered two months or six months following the first shot.
Read More

ECTRIMS opens: Biogen therapies did not reduce COVID-19 antibody responses in MS patients

Oct. 13, 2021
By Lee Landenberger
Biogen Inc. opened the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual meeting with data showing those treated with its multiple sclerosis (MS) therapies had an effective antibody response to COVID-19 vaccination.
Read More

Regulatory actions for Oct. 13, 2021

Oct. 13, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Corium, Curevac, Deciphera, Gensight, Hoth, Intelgenx, Nrx, Ocular, Protara, Sofie, Viiv.
Read More

Other news to note for Oct. 13, 2021

Oct. 13, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aavantibio, ABVC, Acceleron, Agenus, Albireo, Betterlife, Bionova, Biolite Japan, Bristol-Myers Squibb, Emmaus, Fosun, Helsinn, Jadeite, Kainos, Merck, Mission, Rxcell, Sapience, Sutro, Titan.
Read More

In the clinic for Oct. 13, 2021

Oct. 13, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Advaccine, Aerie, Agenus, Apeiron, Arcturus, Ascletis, Astellas, BMS, Inflarx, Inhibrx, Inovio, Istari, Otonomy, Vtv.
Read More

Other news to note for Oct. 12, 2021

Oct. 12, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Diagnostics Research Group, Diomics, Halleck-Willard, Icecure Medical, IMA Group, Integrated Media Technology, Magnum International, Nutriband, SPT Labtech, Steripack.
Read More
Previous 1 2 … 174 175 176 177 178 179 180 181 182 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing